

Disclosures

Personal Commercial (10)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott	Research/Research Grants ‡ <i>Cephea Early Feasibility study</i>	Significant (>= \$5,000)	<i>Valvular Heart Disease</i>
Abbott	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Valvular Heart Disease</i>
Cara Medical Ltd	Research/Research Grants ‡ <i>Cara CDRS</i>	Significant (>= \$5,000)	<i>Valvular Heart Disease</i>
Edwards Lifesciences	Speaker's Bureau	Significant (>= \$5,000)	<i>Valvular Heart Disease</i>
Medtronic	Research/Research Grants ‡ <i>OPTIMIZE PRO</i>	Significant (>= \$5,000)	<i>Valvular Heart Disease</i>
Medtronic	Research/Research Grants ‡ <i>EXPAND II</i>	Significant (>= \$5,000)	<i>Valvular Heart Disease</i>
Medtronic	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Valvular Heart Disease</i>
Medtronic	Speaker's Bureau	Modest (< \$5,000)	<i>Valvular Heart Disease</i>
V-Wave	Research/Research Grants ‡ <i>RELIEVE HF</i>	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
V-Wave Ltd	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i> <i>Invasive CV Angio and Interventions</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (16)

Trial Name	Trial Sponsor	Trial Funding Source
PARADIGM	Abbott	
PORTICO I study	Abbott	
Altavalve Early Feasibility study	Altavalve	
EMPACT-MI	Boehringer Ingelheim Pharmaceuticals, Inc	
AEGIS II	Boehringer Ingelheim Pharmaceuticals, Inc	
ACURATE IDE	Boston Scientific	
Edwards Pascal Pivotal trial	Edwards Lifesciences	
ENCIRCLE	Edwards Lifesciences	
SAPIEN 3 ULTRA system registry	Edwards Lifesciences	
TRISCEND	Edwards Lifesciences	
EXPAND I	MEDTRONIC	
HORIZON	Novartis	
VICTORION 1 Prevent	Novartis	
VICTORION 2 - Prevent	Novartis	
FRONTIERS CAVS	Novartis	

Trial Name	Trial Sponsor	Trial Funding Source
PREVALENCE	Novartis	

Institutional Financial Decision-Making Role (4)

Funding Source	Institutional Compensation Level
Abbott	Significant (>= \$5,000)
Boston Scientific	Significant (>= \$5,000)
Edwards Lifesciences	Significant (>= \$5,000)
MEDTRONIC	Significant (>= \$5,000)

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 4/16/2023
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 4/16/2023
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 4/16/2023
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 4/16/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.